Olink

Olink®
Part of Thermo Fisher Scientific

Oxygen therapy enhances the systemic inflammatory response in a human model of experimental inflammation

IJC Heart & Vasculature, 2025

Tornvall P., Svensson P., Alfredsson J., Jonasson L., Nilsson L., Hofmann R., Merid S.

Disease areaApplication areaSample typeProducts
CVD
Pathophysiology
Plasma
Olink Target 96

Olink Target 96

Abstract

Introduction
Oxygen therapy does not benefit normoxemic patients with suspected myocardial infarction and may instead enhance the inflammatory response triggered by the tissue necrosis caused by the myocardial infarction. In the present study, we tested the hypothesis that oxygen therapy aggravates systemic inflammation in normoxemic healthy individuals in a human model of experimental inflammation.
Methods
Proteomic and gene expression data from healthy subjects vaccinated against Salmonella Typhii and exposed to oxygen therapy or ambient air were investigated. A multi-omics approach with factor analysis to identify common sources of variation in the systemic inflammatory response associated with oxygen exposure was used.
Results
Oxygen therapy showed a statistically nominal tendency toward aggravation determined by ELISA (IL-6) and proximity extension assay (IL-8). The factor analysis revealed a pro-inflammatory feature that included increases in (CXCL 6, 10 and 11) with decreased small nucleolar RNA.
Conclusion
The results indicate that oxygen therapy enhances experimental systemic inflammation. The mechanism is not clear but future studies should address small nucleolar RNA.

Read publication ↗